KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Receivables - Net: 2009-2024

Historic Receivables - Net for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to $3.1 billion.

  • Teva Pharmaceutical Industries' Receivables - Net rose 10.05% to $3.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 billion, marking a year-over-year increase of 10.05%. This contributed to the annual value of $3.1 billion for FY2024, which is 10.24% down from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its Receivables - Net stood at $3.1 billion for FY2024, which was down 10.24% from $3.4 billion recorded in FY2023.
  • In the past 5 years, Teva Pharmaceutical Industries' Receivables - Net ranged from a high of $4.6 billion in FY2020 and a low of $3.1 billion during FY2024.
  • Its 3-year average for Receivables - Net is $3.4 billion, with a median of $3.4 billion in 2023.
  • Data for Teva Pharmaceutical Industries' Receivables - Net shows a maximum YoY decreased of 19.29% (in 2020) over the last 5 years.
  • Over the past 5 years, Teva Pharmaceutical Industries' Receivables - Net (Yearly) stood at $4.6 billion in 2020, then decreased by 1.14% to $4.5 billion in 2021, then declined by 18.39% to $3.7 billion in 2022, then declined by 7.79% to $3.4 billion in 2023, then declined by 10.24% to $3.1 billion in 2024.